Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15170303 | 1.00 | JAK2 (0.51) | JAK2JAK1JAK3GPR119PIK3CD | |
| SCHEMBL671286 | 0.87 | JAK2 (0.49) | JAK2GPR119USP30PRMT5 | |
| SCHEMBL671285 | 0.87 | JAK2 (0.49) | JAK2GPR119USP30PRMT5 | |
| SCHEMBL10075570 | 0.80 | GPR119 (0.51) | JAK2JAK3GPR119USP30PRMT5 | |
| SCHEMBL23537864 | 0.79 | USP30 (0.43) | JAK3GPR119USP30PRMT5 | |
| SCHEMBL23537863 | 0.79 | USP30 (0.43) | JAK3GPR119USP30PRMT5 | |
| SCHEMBL28834338 | 0.77 | USP30 (0.53) | JAK2JAK1GPR119USP30PRMT5 | |
| SCHEMBL28834341 | 0.77 | USP30 (0.53) | JAK2JAK1GPR119USP30PRMT5 | |
| SCHEMBL18107103 | 0.76 | PIK3CD (0.49) | GPR119PIK3CDUSP30IKBKETBK1 | |
| SCHEMBL23537598 | 0.75 | USP30 (0.47) | JAK2JAK1GPR119USP30PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-08-06 | — | — | US | disclosed |
| US-10111875-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHINSON MEDIPHARMA LIMITED (CN) | 2018-10-30 | — | — | US | disclosed |
| EP-2606051-B1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED | 2016-08-11 | — | — | US | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| EP-2606051-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022045-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022265-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
| US-10111875-B2 | Pyrrolopyrimidine compounds and uses thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.